Li C, Lu K, Shi Q, Gong Y
Ther Adv Chronic Dis. 2022; 13:20406223221114214.
PMID: 35924011
PMC: 9340933.
DOI: 10.1177/20406223221114214.
Fobelo Lozano M, Sanchez-Fidalgo S
Eur J Hosp Pharm. 2019; 26(1):4-9.
PMID: 31157088
PMC: 6362767.
DOI: 10.1136/ejhpharm-2017-001258.
Hagino H, Ito M, Hashimoto J, Yamamoto M, Endo K, Katsumata K
J Bone Miner Metab. 2017; 36(3):336-343.
PMID: 28389932
DOI: 10.1007/s00774-017-0839-2.
Tanaka K, Nishimura N, Kawai Y
J Physiol Sci. 2016; 67(2):271-281.
PMID: 28000175
PMC: 10717636.
DOI: 10.1007/s12576-016-0514-8.
Kishimoto H, Maehara M
Arch Osteoporos. 2015; 10:231.
PMID: 26297076
PMC: 4545179.
DOI: 10.1007/s11657-015-0231-6.
A Review of Patient Preferences for Osteoporosis Drug Treatment.
Hiligsmann M, Bours S, Boonen A
Curr Rheumatol Rep. 2015; 17(9):61.
PMID: 26286178
PMC: 4540772.
DOI: 10.1007/s11926-015-0533-0.
Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P, Papaioannou N, Gielen E, Feudjo Tepie M, Zhang E, Frieling I
Osteoporos Int. 2015; 26(10):2479-89.
PMID: 26018090
PMC: 4575374.
DOI: 10.1007/s00198-015-3164-4.
Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
Nakamura T, Ito M, Hashimoto J, Shinomiya K, Asao Y, Katsumata K
Osteoporos Int. 2015; 26(11):2685-93.
PMID: 26001561
PMC: 4605968.
DOI: 10.1007/s00198-015-3175-1.
Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).
Iwamoto J, Okano H, Furuya T, Urano T, Hasegawa M, Hirabayashi H
J Bone Miner Metab. 2015; 34(2):201-8.
PMID: 25794468
DOI: 10.1007/s00774-015-0653-7.
The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
Hadji P, Felsenberg D, Amling M, Hofbauer L, Kandenwein J, Kurth A
Osteoporos Int. 2013; 25(1):339-47.
PMID: 24091594
DOI: 10.1007/s00198-013-2515-2.
Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass.
Hadji P, Ziller V, Gamerdinger D, Spieler W, Articus K, Baier M
Osteoporos Int. 2011; 23(7):2043-51.
PMID: 22086310
DOI: 10.1007/s00198-011-1834-4.
Osteoporosis Patient Treatment Satisfaction Questionnaire in postmenopausal women intermittently treated with oral bisphosphonates: the BRAVO study.
Oh K, Kim D, Lee Y, Kang M
J Bone Miner Metab. 2011; 30(3):359-66.
PMID: 22083905
DOI: 10.1007/s00774-011-0326-0.
Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
Lee Y, Song G
Korean J Intern Med. 2011; 26(3):340-7.
PMID: 22016595
PMC: 3192207.
DOI: 10.3904/kjim.2011.26.3.340.
Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.
Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker R, Felsenberg D
Osteoporos Int. 2011; 23(6):1769-78.
PMID: 21975558
DOI: 10.1007/s00198-011-1793-9.
Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia.
Vlak T, Kastelan D, Lozo P, Aljinovic J, Gradiser M, Mijic S
Clin Rheumatol. 2011; 30(12):1549-54.
PMID: 21956235
DOI: 10.1007/s10067-011-1858-3.
Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™.
Barrett-Connor E, Wade S, Do T, Satram-Hoang S, Stewart R, Gao G
Osteoporos Int. 2011; 23(2):733-41.
PMID: 21625886
DOI: 10.1007/s00198-011-1620-3.
Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
Hadji P, Gamerdinger D, Spieler W, Kann P, Loeffler H, Articus K
Osteoporos Int. 2011; 23(2):625-33.
PMID: 21442459
DOI: 10.1007/s00198-011-1583-4.
Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.
Kendler D, McClung M, Freemantle N, Lillestol M, Moffett A, Borenstein J
Osteoporos Int. 2010; 22(6):1725-35.
PMID: 20827547
DOI: 10.1007/s00198-010-1378-z.
Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment.
Huas D, Debiais F, Blotman F, Cortet B, Mercier F, Rousseaux C
BMC Womens Health. 2010; 10:26.
PMID: 20727140
PMC: 2941476.
DOI: 10.1186/1472-6874-10-26.
Low acceptance of treatment in the elderly for the secondary prevention of osteoporotic fracture in the acute rehabilitation setting.
Berry S, Misra D, Hannan M, Kiel D
Aging Clin Exp Res. 2010; 22(3):231-7.
PMID: 20634646
PMC: 2919059.
DOI: 10.1007/BF03324801.
